Haemonetics Corporation (HAE) Director Pedro P. Granadillo Sells 7,118 Shares
Haemonetics Corporation (NYSE:HAE) Director Pedro P. Granadillo sold 7,118 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $57.06, for a total value of $406,153.08. Following the completion of the transaction, the director now owns 31,663 shares in the company, valued at $1,806,690.78. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Haemonetics Corporation (NYSE:HAE) traded down $1.27 during trading hours on Monday, reaching $56.34. The company’s stock had a trading volume of 408,858 shares, compared to its average volume of 355,050. Haemonetics Corporation has a fifty-two week low of $36.44 and a fifty-two week high of $58.99. The company has a market cap of $3,042.86, a PE ratio of 35.34, a PEG ratio of 4.33 and a beta of 0.99. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22.
Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.07. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The firm had revenue of $225.40 million during the quarter, compared to analyst estimates of $219.12 million. During the same period last year, the firm posted $0.38 EPS. The business’s revenue was up 2.3% compared to the same quarter last year. equities research analysts forecast that Haemonetics Corporation will post 1.7 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in HAE. Shine Investment Advisory Services Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter valued at $132,000. Riverhead Capital Management LLC increased its position in shares of Haemonetics by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 1,507 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Haemonetics during the 2nd quarter valued at $174,000. Shelton Capital Management purchased a new stake in shares of Haemonetics during the 2nd quarter valued at $204,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Haemonetics during the 2nd quarter valued at $260,000.
Several equities analysts have weighed in on the company. BidaskClub upgraded Haemonetics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 8th. TheStreet upgraded Haemonetics from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $48.00 price objective on the stock in a research note on Thursday, August 17th. Barrington Research upgraded Haemonetics from a “market perform” rating to an “outperform” rating and set a $48.00 price objective on the stock in a research note on Tuesday, August 8th. Finally, Craig Hallum restated a “hold” rating and set a $50.00 price objective (up from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $53.33.
Haemonetics Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.